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Introduction: Therapeutic potentials of mesenchymal stem cells (MSCs) from different sources have been evaluated
in pre-clinical and clinical settings. Although MSCs from different sources share MSC-specific characteristics and
functions, inconsistent or controversial results of pre-clinical and clinical applications of such cells are frequently
reported. This may be partially due to the fact that MSCs isolated from different origins may differentially express
some functions not typical for MSCs, and hence have different therapeutic potentials. The aim of this study is to
investigate the differences in human placental MSCs (P-MSCs) of fetal and maternal origins in the aspects of
clinical importance.
Methods: P-MSCs of fetal and maternal origins isolated from normal term placentas were characterized for their
typical phenotype as well as their expression of receptors and growth factors of clinic interests. P-MSCs that
preferentially express hepatocyte growth factor (HGF) and CD200 were evaluated for their therapeutic potentials
in models of angiogenesis and allogeneic skin transplantation, in comparison with their HGF and CD200
negative partners.
Results: Although all P-MSCs express typical MSC phenotype, fetal but not maternal P-MSCs express high
levels of CD200 and HGF. Compared with HGF and CD200 negative P-MSCs, HGF and CD200 positive cells
demonstrated significantly high potentials in promoting angiogenesis in vitro and increasing immunosuppressive
function in vivo. These therapeutic potentials were at least in part due to their differences in HGF and CD200
expression, respectively.
Conclusions: We conclude that MSC origins may have significant impact on the therapeutic potentials of such cells,
and should be taken into consideration in clinical applications.Introduction
Mesenchymal stem cells (MSCs) are considered one of
the most promising cell types for therapeutic applica-
tions and are, hence, most intensively evaluated in pre-
clinical and clinical settings. The characteristics that
demonstrate MSC’s high therapeutic potentials include
the potential for multiple lineage differentiation [1], the
ability of secreting growth factors that can promote cell* Correspondence: dreamcell@live.cn; yukuili@hotmail.com
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reproduction in any medium, provided the orgrowth and tissue repair [2]; the function of immunomo-
dulation and immunosuppression [3]; and the limited
expression of major histocompatibility complex (MHC)
II and co-stimulating molecules which allow MSCs to be
used across MHC barriers [4]. Equally noteworthy, not
all these characteristics are equally expressed in MSCs of
different origins, or in MSCs prepared under different
conditions. For instance, CD200, a cell surface molecule
mediating an immunosuppressant signal, is expressed in
significant levels in some bone marrow-derived MSCs
but marginal levels in others, and almost undetectable in
MSCs of umbilical cord blood origin [5]. Also, matrix
metalloproteinases (MMPs), the molecules that mediate
multiple cell-cell interactions and functions of MSCs,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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tion conditions but not under normal physical condi-
tions [6]. Such differences may have significant impact
on the outcome of clinical treatments when the MSCs
are used for cell therapies. For example, hepatocyte
growth factor (HGF) is expressed by some MSC cultures
[7]. Standal et al. [8] reported that HGF decreased bone
morphogenetic protein (BMP)-induced osteoblast activ-
ity and, hence, increased bone loss, in multiple myeloma
(MM) bones, and Xu et al. [9] reported that bone
marrow-derived MSCs (BM-MSCs) promoted MM cell
growth, protected MM cells from drug-induced apop-
tosis, and shortened the life span of MM-bearing mice,
while Li et al. [10] demonstrated that placenta-derived
MSC-like cells prevented bone loss, stimulated bone
formation and suppressed growth of MM in mouse
bone. Similar inconsistencies of the therapeutic effects
of MSCs from different origins or different preparations
on tumor growth have been well documented [11].
These studies together support a notation that MSCs
of different origins or prepared under different condi-
tions may express different functions and have different
therapeutic potentials.
Of the different sources of MSCs so far investigated,
human term placentas have drawn increased interest in
recent years [12,13], due mainly to their non-invasive
donor procurement and large MSCs supply, in addition
to their sharing the basic properties with BM-MSCs
[14-17]. A human placenta contains MSCs of both fetal
and maternal origin. We [18] and others [13,19,20] have
previously isolated and characterized fetal and maternal
MSCs from human placentas. Compared with placental
MSCs (P-MSCs) of maternal origins, fetal MSCs have
demonstrated stronger immunomodulatory function and
higher osteogenic differentiation potential [13,20]. How-
ever, the defined properties of these cells relevant to
therapeutic applications are still poorly understood. In
the present report, we tested the differences between P-
MSCs of fetal and maternal origins in the aspects of
immunosuppressant molecule expression, growth factor
secretion, and functions in stimulating angiogenesis and
modulating immunosuppression. The results suggest
that MSC origins may have significant impact on the
therapeutic potentials of such cells, and should be taken
into consideration in clinical applications.
Materials and methods
Animals
C57BL/6 and Vr:CD1(ICR) mice were obtained from
the Surgical Experiment Center of Ningxia General
Hospital Affiliated Ningxia Medical University. All ani-
mal studies were performed with a protocol approved
by the committee of animal care and use at the Ningxia
Medical University.P-MSCs cell isolation and culture
Human full-term placentas were obtained from healthy
mothers at the time of routine elective caesarean section
in the Affiliated Hospital of Ningxia Medical University.
Informed consent was obtained from each mother prior
to delivery. Human placental tissues were collected with
a protocol approved by the Ethics Committee for the
Conduct of Human Research at Ningxia Medical Univer-
sity. The Human Research Ethics Committee at Ningxia
Medical University approved this study. Fetal and maternal
P-MSCs were isolated and genetic origin verified as de-
scribed previously [18]. The cells were cultured in Dulbec-
co’s Modified Eagle Medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 2 mM L-glutamine and
50 μg/ml gentamycin (Invitrogen, Carlsbad, CA, USA). This
medium is referred to as P-MSC medium. All cultures
were maintained at 37°C in a humidified incubator with
5% CO2. At about 90% confluence, the cells were passaged
after detachment with TrypLE™ Express (Invitrogen). All
the studies were performed with five passages of the estab-
lished P-MSCs cultures.Flow cytometry
P-MSCs were harvested by TrypLE™ Express treatment
and analyzed by flow cytometry with a FACS Calibur flow
cytometer (BD Biosciences, San Diego, CA, USA). All
monoclonal antibodies used for flow cytometry were ob-
tained from BD Pharmingen (Franklin Lakes, NJ, USA)
and prepared in PBS. Cells (1 × 106) in 100 μl were incu-
bated with 10 μl of one of the following antibodies for
20 minutes at room temperature: IgG1-PE, CD34-PE,
CD73-PE, IgG2a-FITC, CD14-FITC, CD45-FITC, CD90-
FITC, CD105-FITC, CD200-PE or HLA-DR-FITC. After
washing, cells were resuspended in 500 μL PBS and phe-
notyped by flow cytometry analysis.RNA isolation and qRT-PCR
Cultured fetal and maternal P-MSCs in passage 5 were
washed with PBS and total RNA was isolated with Trizol
Reagent (Invitrogen). cDNA was elaborated from RNA
using Revert Aid First Strand cDNA Synthesis Kit
(Thermo Fisher Scientific, San Diego, CA, USA). Quan-
titative PCR (qPCR) was carried out using the DyNAmo*
Capillary SYBR* Green 2-Step qRT-PCR Kit (Thermo
Fisher Scientific). Thermal cycling conditions were 95°C
for 10 minutes followed by 40 cycles of 15 s at 95°C,
followed by 1 minute at 60°C. We obtained melt data by
30 minutes at 60°C. PCR primer sets for CD200, HGF
and GAPDH were: CD200: forward 5′- AATACCTTTG
GTTTTGGGAAGATCT-3′, reverse 5′-GGTGGTCTTC
AGAGAATTTGTAGTGA-3′; HGF: forward 5′-ATTGC
CCTATTTCTCGTTGTG-3′, reverse 5′-GCATTTCTC
ATCTCCTCTTCC-3′; GAPDH; forward 5′-AACATCA




Equal numbers of fetal and maternal P-MSCs in passage 5
were seeded into 35 mm-Petri dishes, respectively, and
cultured in normal medium (as described above) with or
without 10 ng/ml IFN-γ (R&D Systems, Inc., Wiesbaden,
Germany) or 1 μM poly (I:C) (Invivogen, San Diego,
USA) (final concentration) for 72 h. At the end of cell cul-
ture, cell numbers were re-counted and supernatants of
each culture were collected for ELISA analysis. All ELISA
kits were obtained from BOSTER (Wuhan, China). ELISA
analysis was performed according to the manufacturer’s
protocol. The concentration of each cytokine secreted by
P-MSCs is normalized with the cell number at the end of
experiments and expressed as pg/ml/105 cells.
Preparation of P-MSC-conditioned medium
Maternal and fetal P-MSCs in passage 5 were seeded at
1 × 106 cells/100 mm plate with 10 ml P-MSCs medium
and cultured for 48 hours. After this cultivation period,
medium from each culture was collected and clarified by
centrifugation at 1,000 rpm for 10 minutes at 4°C. These
media were referred to as maternal and fetal P-MSC-
conditioned medium, respectively.
In vitro angiogenesis assay
Growth factor-reduced Matrigel (BD Biosciences) was
thawed at 4°C overnight and spread evenly over 48-well
plates pre-chilled at 4°C. The plates were incubated for
30 minutes at 37ºC to allow gel formation. Human umbil-
ical vein endothelial cells (HUVECs) (BIOLEAF, Shanghai,
China) were cultured in DMEM with 10% FBS, 50 U/ml
penicillin and 50 ug/mL streptomycin (Invitrogen). Cells
that reached 80% confluency were collected by trypsiniza-
tion and centrifugation. Single cell suspensions were
prepared in P-MSCs medium, P-MSCs medium plus
20 ng/ml recombinant human growth factor (rhHGF)
(R&D System), maternal P-MSC-conditioned medium,
fetal P-MSC-conditioned medium, and fetal P-MSC-
conditioned medium plus 100 ng/ml anti-human HGF
antibody (R&D System). A total of 3.5 × 104 cells in
500 μl of each medium were evenly seeded over a
Matrigel-coated well of 48-well plates. After incubation
for 12 hours, the cultures were imaged under a micro-
scope and the numbers of capillary tube structures were
counted from nine randomly chosen fields for each
culture condition.
Skin transplantation
Vr:CD1(ICR) mice at postnatal Day 3 were used as skin
donors, and C57BL/6 mice at age 8 to 10 weeks of
age were used as recipients. The donor mice weresacrificed with CO2, and then skin grafts of 1.2 cm in
diameter were prepared using a surgical puncher. The
recipient mice were anesthetized with chloral hydrate
(Sangon Biotech, Shanghai, China), and a round incision
of 1.2 cm in diameter was made on the dorsal side of
each recipient mouse. After the removal of full-thickness
skin from the incision sites of the recipient mice,
donor skin grafts were transplanted into the sites, and
dressed with Vaseline dressings and Band-Aids. At the
time of the skin transplantation, the recipient mice
were injected (tail i.v.), respectively, with 200 μl PBS,
1 × 105 maternal P-MSCs in 200 μl PBS, 1 × 105 fetal
P-MSCs in 200 μl PBS and 1 × 105 CD200 blocked
fetal P-MSCs. The CD200 of fetal P-MSCs was blocked
by using mouse anti-human PE-conjugated CD200 anti-
body according to the method derived from Mika
Pietila et al. [5]. Briefly, fetal P-MSCs were incubated
with anti-human CD200 antibody (BD Biosciences) at
20 μl antibody/1 × 106 cells in 100 μl PBS for 30 minutes
and then washed twice with PBS and suspended in PBS.
Grafts were inspected daily from the third day of trans-
plantation to establish time of rejection.
Statistical analysis
All statistical analyses were performed using SPSS statis-
tical analysis software (SPSS Inc., Chicago, IL, USA). Re-
sults were expressed as mean ± SD for illustration. The
statistical significance in differences among treatments
was determined using one-way ANOVA with a post-hoc
least square difference (LSD) test. A P-value of less than
0.05 was considered significant.
Results
Fetal, but not maternal, P-MSCs preferentially express
CD200
The P-MSCs of fetal and maternal origins were isolated
and characterized as previously described [18]. For matched
comparison, the cells were maintained under the same con-
ditions and exposed to the same treatments throughout the
experiments, and the results were compared in pairs of in-
dividual placenta donors. Both fetal and maternal P-MSCs
express typical MSC morphology and phenotype, they
all share the similar spindle-like shape (Figure 1A), as
well as being positive for CD73, CD90 and CD105, and
negative for CD14, CD45, CD34 and MHC class II recep-
tor HLA-DR (Figure 1B). Since CD200 has been shown to
mediate the immunosuppressive function to multiple
myeloid cell types, especially to dendritic cells and macro-
phages [21,22], we tested the expression of this molecule
in P-MSCs. As shown in Figure 1B, CD200 positive cells
count for about 70% of the fetal P-MSCs population, while
being barely detectable in maternal P-MSCs. To confirm
this finding, we further isolated P-MSCs from three ran-
dom donors, and analyzed CD200 expression by qPCR
Figure 1 Fetal and maternal P-MSCs commonly express a MSC-specific phenotype, but differentially express CD200. A: The morphology
of maternal and fetal P-MSCs. B: Flow cytometry analysis for PMS-specific phenotype expression by fetal and maternal P-MSCs. Both populations
expressed typical MSC phenotype. C and D: Comparison in CD200 expression in transcript (C) and protein (D) levels between fetal and maternal
P-MSCs. Shown are representatives of three random donors. **: P <0.01. MSC, mesenchymal stem cells; P-MSCs, placental mesenchymal
stem cells.
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scripts in fetal P-MSCs from the three donors averaged
more than 10 times that in maternal P-MSCs (Figure 1C).
This finding was further confirmed in protein levels. Flow
cytometry demonstrated that CD200+ cells were con-
stantly identified in fetal P-MSCs but not in maternal
P-MSCs from all three random donors. As CD200 medi-
ates multiple lines of immunosuppressive signals, this re-
sult may suggest higher potential of fetal P-MSCs for
immunosuppressant treatments.Fetal P-MSCs express significantly higher levels of HGF
than do maternal P-MSCs
HGF is an important growth factor that not only pro-
motes cell growth, morphogenesis and tissue regener-
ation [23], but also exerts a regulatory role in inducing
tolerogenic dendritic cells and regulatory T cells [24].
We examined HGF along with interleukins 6 (IL-6), 8
(IL-8), 10 (IL-10) and TNF-α expressed in P-MSCs of
fetal and maternal origins in cell number-controlled set-
tings (see Materials and methods). Surprisingly, while
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cell populations, fetal P-MSCs expressed a much higher
level of HGF, about 100 times as much as expressed by
maternal P-MSCs do (Figure 2A). We further verified this
finding by qPCR for transcript expression of HGF. As
shown in Figure 2B, a significant difference in HGF
transcript expression comparable with protein secretion
was observed. This result suggests that a superior bene-
fit may be expected for therapeutic applications of fetal
P-MSCs over P-MSCs of maternal origin.
Fetal and maternal P-MSCs responded to
immunostimulation with discrete cytokine pathways
It has been previously reported that interferon gamma
(INF-γ) and Toll like receptor-3 ligand poly (I:C) can
induce activation and enhance therapeutic potential
of MSCs [3,25]. We sought next to elucidate how the
P-MSCs of fetal and maternal origin respond to these
immune stimuli. Although both cell types responded to
the stimuli significantly in the aspect of cytokine induc-
tion (Figure 3), they showed discrete cytokine response
patterns. Upon INF-γ stimulation, fetal P-MSCs signifi-
cantly increased IL-6 secretion, and decreased to a lesser
but statistically significant extent the secretion of IL-8,
IL-10 and HGF; in comparison, in maternal P-MSCs,
INF-γ induced significant increases in IL-6, IL-10 and
HGF (Figure 3A,B). Considering the immunomodula-
tory and anti-inflammation properties of IL-10 and HGF,
this observation may suggest that INF-γ-priming may be
more preferable for maternal P-MSCs than fetal P-MSCs
when immunomodulation applications are considered
for these cells.
Markedly different from INF-γ, Poly (I:C) stimulation
resulted in a significantly increased secretion of IL-8 in
maternal P-MSCs but not fetal P-MSCs, and a signifi-
cantly increased secretion of HGF in fetal but notFigure 2 Differential cytokine expression by fetal and maternal P-MSC
equal numbers and re-counted at the end of culture. Cytokine levels in cel
numbers at the end of the study. B: qPCR quantification for HGF expression
growth factor; P-MSCs, placental mesenchymal stem cells.maternal P-MSCs. (Figure 3C,D). Whether the different
responses are due to differentiated expression of TLR-3
in these two cell populations is unknown and need to be
further explored.
Fetal P-MSCs stimulated angiogenesis of HUVECs in vitro
HGF is well known for its function in stimulating angio-
genesis of endothelial cells. Having observed that the
P-MSCs of fetal origin expressed a much higher level of
HGF in both mRNA and protein than P-MSCs of mater-
nal origin (Figure 2), we next tested if this difference
would translate into differences in their ability to stimu-
late angiogenesis. As shown in Figure 4, the human um-
bilical vein-derived endothelial cells (HUVECs) grew
into a limited number of tube structures when cultured
in the absence of HGF. When human recombinant HGF
was added to the culture, significantly more tube struc-
tures were observed. In comparison, when HUVECs
were cultured in fetal P-MSCs-conditioned medium,
tube formation was enhanced to the level similar to
HGF-treated cultures. This enhancement in angiogenesis
was not observed when HUVECs were cultured in mater-
nal P-MSCs-conditioned medium, and was inhibited by the
addition of anti-HGF antibodies (Figure 4A,B). These re-
sults demonstrated that, compared with maternal P-MSCs,
fetal P-MSCs expressed an increased ability to stimulate
in vitro angiogenesis, and it is suggestive, though not con-
clusive, that this function is dependent on HGF secretion.
Fetal P-MSCs prolonged skin allograft survival through
CD200 expression
MSCs are known to have immunosuppressive func-
tions. CD200 is a negative regulator of a number of im-
mune cells, predominantly cells of myeloid origin. Since
P-MSCs of fetal origin expressed much higher CD200
than P-MSCs of maternal origin, we reasoned the CD200-s. A: P-MSC cells from fetal and maternal P-MSCs were seeded in
l culture supernatants were quantified by ELISA and normalized by cell
by fetal and maternal P-MSCs. n = 3. **: P <0.01. HGF, hepatocyte
Figure 3 Cytokine expression by fetal and maternal P-MSCs in response to IFN-γ and Poly (I:C) stimulations. Equal numbers of cells
from fetal and maternal P-MSCs were seeded and stimulated with IFN-γ (A) and Poly (I:C) (B). Cytokine levels in cell culture supernatants were
quantified by ELISA and normalized by cell numbers at the end of the study. n = 3. *: P <0.05, **: P <0.01. IFN-γ, interferon gamma; P-MSCs,
placental mesenchymal stem cells.
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functions. This was tested in a mouse skin allograft model.
As shown in Figure 5, without immunosuppressant, skin
allografts were rejected within six days. When the recipi-
ent mice received an IV injection of fetal P-MSCs, the al-
lografts survived to 10 days on average. When anti-CD200
antibodies were injected into the CD200-expressing cell-
treated mice, the graft survival time was reduced to an
average of eight days, similar to the survival time in mice
treated with CD200-negative cells. These results indicated
that fetal P-MSCs prolonged allograft survival, partially
but not totally, due to CD200-mediated immunosuppres-
sion. Maternal P-MSCs (CD200 negative MSCs) could
also increase allograft survival, but to a significantly lower
extent than did fetal P-MSCs (CD200 positive MSCs).
Discussion
MSCs are one of the most promising types of stem cells
for recent clinical applications. One existing problem fre-
quently reported with this cell type is the inconsistent
or controversial results from pre-clinical and clinical
applications, possible reasons, among others, being the
different impacts from the sources of the cells, culture
systems used and the ratio of different sub-groups with dif-
ferent properties/functions of cells in a given heterogeneouspopulation. In the present study, we started to address this
problem by studying paired MSC populations of fetal and
maternal origin from the same tissues (individual placentas)
and under tightly controlled conditions for their difference
in the aspects of clinical relevance. These settings allowed
us to define the impact of developmental sources of MSC
populations to the cell properties/functions. In this report
we have demonstrated that fetal but not maternal P-MSCs
express high levels of CD200 and HGF, and respond differ-
ently to immunostimulations in terms of cytokine secretion.
Since CD200 and HGF have significant clinical rele-
vance, we further demonstrated that, compared with
maternal P-MSCs, fetal P-MSCs predominantly express
CD200 and HGF prolonged skin allograft survival in vivo
and stimulated angiogenesis in vitro, respectively.
MSCs from multiple different tissues have been isolated
and characterized. Although bone marrow MSCs remain the
most frequently investigated MSC populations, MSCs from
different neonatal tissues have recently drawn special
attention [26], due in part to their being ethically non-
controversial, easily accessible and MSC-enriched. These
MSC origins include amniotic membrane and chorionic
membrane [27,28], whole placenta [29], Wharton’s jelly [30]
and whole umbilical cord [31]. Comparative studies have in-
dicated that different cell sources may have significant impact
Figure 4 Fetal P-MSCs (fPMSCs) stimulated angiogenesis in vitro in HGF-dependent manner. (A) Tube formation by HUVECs cultured in
P-MSCs medium, P-MSCs medium supplemented with 20 ng/mL rhHGF, maternal P-MSCs conditioned medium (mPMSCs cM), fetal P-MSCs
conditioned medium (fPMSCs cM) and fPMSCs cM plus100 ng/mL anti-HGF antibody, respectively. Images are representatives of nine randomly
chosen images for each culture condition (100x magnification). (B) The average number of tube structures formed in each group as counted from
nine randomly chosen images under 40x magnification. **: P <0.01. HGF, hepatocyte growth factor; HUVECs, human umbilical vein endothelial
cells; P-MSCs, placental mesenchymal stem cells; rhHGF, recombinant human growth factor.
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the MSCs from bone marrow, umbilical cord blood and
adipose tissue for their stem cell characteristics under identi-
cal in vitro conditions, and demonstrated that, although
phenotypically similar, these MSC populations exhibited cell
source-related heterogeneity in colony frequency, prolifera-
tive capability and differentiation potential. Hwang et al. [33]
demonstrated that MSCs from placenta, cord blood and
bone marrow expressed different cytokine profiles. Gaebel et
al. [34] compared MSCs from umbilical cord blood, adipose
tissue and bone marrow for their ability to promote cardiac
regeneration, and found that MSCs from different sources
showed a different healing performance. In our current
study, we demonstrated that P-MSCs from the same pla-
centa but different developmental origins have different
properties of therapeutic importance, and we further linked
these properties to the differential expression of CD200 and
HGF by these two MSC populations. These studies
altogether support a note that the sources where the MSCs
originate may have a significant impact on the therapeutic
potential of the cells.Among the differences between fetal and maternal P-
MSCs identified in our current study, CD200 and HGF
are of specific interest. CD200 is a cell surface glycopro-
tein mediating an immunosuppressant signal, and has
been shown to modulate immune responses by multiple
myeloid cell types, especially to dendritic cells and mac-
rophages [21,22]. It has been recently reported that cells
expressing the CD200 transgene could prolong allograft
skin survival [35], and a similar function was demonstrated
by using anti-CD200 antibodies [36]. In our present study,
we demonstrated that fetal but not maternal P-MSCs
expressed CD200 to a significant level, and this expres-
sion mediated an anti-rejection function in a mouse
skin allograft model. MSCs have been well known for
their immunomodulative functions and hence have
been tested in multiple clinical settings. Expression of
CD200 by MSCs can be thus expected to add clinical
benefit when MSCs are applied for immunosuppressive
treatments. Pietilä et al. has reported that CD200 was
detected in some but not all bone marrow-derived
MSC populations and was undetectable in umbilical
Figure 5 Fetal P-MSCs (fPMSCs) prolonged skin allograft survival. (A) Representative images of skin allograft survival in different time points
post-transplantation. Different groups show mice treated with PBS, maternal P-MSCs (mPMSCs), fPMSCs and fPMSCs plus anti-CD200 antibodies,
respectively. Images are representative of 10 mice for each group. (B) Skin allograft survival and average survival times among different mouse
groups. n = 10. **: P <0.01. PMSCs, placental mesenchymal stem cells.
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study is the first to report the expression of CD200 in
placental MSCs and CD200-mediated immunosuppres-
sion by fetal P-MSCs. This finding may provide new
insight into the therapeutic potentials of MSCs of neo-
natal origin. Another finding of particular interest is
the preferential expression of HGF by fetal P-MSCs.
HGF is a clinically important growth factor that can
promote angiogenesis and tissue repair. MSCs have
been clinically tested for promoting tissue regeneration
and wound healing. Sasaki et al. reported that MSCs
contributed to wound repair by transdifferentiation into
multiple skin cell types [37]. Wu et al. demonstrated
that MSCs enhance wound healing through differenti-
ation and angiogenesis [38]. Chronic wounds and dia-
betic ulcers, for example, are generally characterized by
hyper-inflammation and impaired angiogenesis. While
it is possible that MSCs can exert both roles against
both dysfunctions, expression of HGF by these cells
can be expected to generate enhanced angiogenesis and
wound healing. In our study, HGF is highly expressed
by fetal P-MSCs but not their partners of maternal ori-
gin, indicating that choosing the appropriate MSC typecan be expected to generate better clinical outcomes. In this
report, we showed evidence that fetal MSC-conditioned
medium, similar to recombinant HGF, stimulated angio-
genesis in vitro and that the anti-HGF antibody abolished
this effect, suggesting the involvement of HGF in MSC-
mediated angiogenesis. This experiment, however, could
not exclude an off-target effect by the antibody and,
hence, did not exclusively prove, though it suggested,
that the observed angiogenesis is mediated by HGF ex-
pression of MSCs. Compared with the maternal P-MSCs
that did not express HGF and failed to stimulate angio-
genesis, however, the study clearly demonstrated that
fetal but not maternal P-MSCS have the ability to en-
hance angiogenesis. The ultimate demonstration of the
mechanisms underlying MSC-mediated angiogenesis is
yet to be explored.
Conclusions
Compared with maternal P-MSCs, fetal P-MSCs express
constitutively higher levels of CD200 and HGF, and this
difference can mediate different potentials of immunosup-
pression in vivo and stimulating angiogenesis in vitro, re-
spectively. Taking into consideration that, in the present
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experimental conditions, and all results were compared
between cell population pairs from the same individual
donors, the results may suggest that, in general, the
sources where the P-MSCs originate may have significant
impact on the therapeutic potential of the cells, and, spe-
cifically, fetal P-MSCs may be more favorable for applica-
tions in cell regeneration, tissue repair and autoimmune
disorders where HGF and CD200 may exert a positive ef-
fect, and less favorable for applications in immune sup-
pressive cancers where CD200 may mediate breakdown of
immunosurveillance and establishment of immune toler-
ance, or for applications where HGF may enhance tumor-
supportive angiogenesis.
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